What is the recommended evaluation and management for a suspected subdural hematoma, including imaging, surgical indications, anticoagulation reversal, and medical care?

Management of Subdural Hematoma

Acute subdural hematomas with thickness >5 mm or midline shift >5 mm require urgent surgical evacuation via craniotomy, while those with thickness >10 mm or midline shift >5 mm mandate immediate surgery regardless of neurological status. 1

Initial Evaluation and Imaging

• Obtain non-contrast CT head immediately to assess hematoma thickness, midline shift, and mass effect 2, 3
• Measure specific parameters: hematoma thickness, degree of midline shift (5 mm threshold is critical), and presence of concurrent injuries (subarachnoid hemorrhage, contusions) 1, 4
• Laboratory workup must include: PT, PTT, INR, and platelet count immediately upon presentation 3
• Consider CT angiography in severe cases where neurological examination is limited or when vascular injury is suspected 1

Surgical Indications

Immediate Surgery Required:

• Thickness >10 mm OR midline shift >5 mm, regardless of Glasgow Coma Scale (GCS) score 5
• Any symptomatic acute subdural hematoma requiring intervention 1
• **GCS <9 with thickness <10 mm and shift <5 mm** IF any of the following: GCS decline ≥2 points from injury to admission, asymmetric/fixed dilated pupils, or ICP >20 mmHg 5

Conservative Management Acceptable:

• Hematomas ≤3 mm rarely require surgery and can be observed, though 11% may enlarge (maximum to 10 mm) 4
• Thickness <10 mm and shift <5 mm in neurologically stable patients without the above deterioration criteria 5

Anticoagulation Reversal

Warfarin/Vitamin K Antagonists:

• Administer four-factor prothrombin complex concentrate (PCC) 50 U/kg for immediate reversal 1
• Vitamin K 10 mg IV should be given concurrently for sustained reversal 1

Direct Oral Anticoagulants (DOACs):

For Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban):

• Give four-factor PCC 50 U/kg OR activated PCC 50 U/kg if bleeding occurred within 3-5 half-lives or in liver failure 1
• Reversal should be guided by bleeding severity, not laboratory values 1

For Dabigatran:

• Idarucizumab is first-line if available 1
• Hemodialysis if idarucizumab unavailable and renal insufficiency present 1

Heparin:

• IV protamine sulfate 1 mg per 100 units of heparin given in preceding 2-3 hours (maximum 50 mg single dose) 1
• Repeat 0.5 mg protamine per 100 units heparin if aPTT remains elevated 1
• Prophylactic subcutaneous heparin reversal only if aPTT significantly prolonged 1

Low Molecular Weight Heparin (LMWH):

• Protamine 1 mg per 1 mg enoxaparin if given within 8 hours (maximum 50 mg) 1
• Protamine 0.5 mg per 1 mg enoxaparin if given 8-12 hours prior 1

Antiplatelet Agents:

• Platelet transfusion for therapeutic antiplatelet use in surgical candidates, though this is associated with longer operative times and higher palliative care consultation rates 6
• Do NOT routinely reverse prophylactic doses 1

Medical Management

Airway and Ventilation:

• Intubate if GCS <9 with controlled ventilation and end-tidal CO2 monitoring 1
• Maintain PaCO2 35-40 mmHg (avoid hypocapnia which causes cerebral vasoconstriction and ischemia) 1
• Target PaO2 >60 mmHg 2

Hemodynamic Goals:

• Maintain ICP <22 mmHg 2
• Cerebral perfusion pressure (CPP) >60 mmHg 2
• Mean arterial pressure (MAP) 80-110 mmHg 2

ICP Management:

• Place ICP monitor in all comatose patients (GCS <9) with acute subdural hematoma 5
• External ventricular drainage for persistent intracranial hypertension despite sedation and correction of secondary insults 1
• Decompressive craniectomy (large temporal >100 cm²) as rescue for refractory intracranial hypertension in multidisciplinary discussion, though age considerations apply (typically <60-70 years) 1

Seizure Management:

• Administer anti-seizure prophylaxis in acute phase 2
• Monitor for seizures given high risk in this population 2

Supportive Care:

• Maintain normothermia, eucarbia, euglycemia, and euvolemia 2
• Early enteral feeding, mobilization, and physical therapy 2
• Avoid hypotension when administering sedatives (barbiturates, midazolam boluses, opioid boluses can cause arterial hypotension) 1

Surgical Technique

• Craniotomy with or without bone flap removal is the preferred surgical approach for acute subdural hematoma evacuation in comatose patients 5
• Surgery should be performed as soon as possible once indication established 5
• Duraplasty may be performed as needed 5

Key Predictors of Expansion

Risk factors for hematoma enlargement include: larger initial size, concurrent subarachnoid hemorrhage, hypertension, convexity location, and initial midline shift 4. An initial size of 8.5 mm best predicts need for surgical intervention (AUC 0.81) 4.

Emerging Therapies

Middle meningeal artery embolization (MMAE) is increasingly used for chronic subdural hematomas, with multiple randomized trials showing efficacy in promoting resorption and reducing recurrence 7. This represents a minimally invasive alternative, particularly for chronic presentations, though surgical evacuation remains standard for acute symptomatic cases 7.